Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/15289
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chanpattana W. | - |
dc.date.accessioned | 2021-04-05T04:33:25Z | - |
dc.date.available | 2021-04-05T04:33:25Z | - |
dc.date.issued | 2000 | - |
dc.identifier.issn | 1252208 | - |
dc.identifier.other | 2-s2.0-0034201252 | - |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/15289 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034201252&partnerID=40&md5=4cc70182a78ae9f50bd22a8080cdcfc8 | - |
dc.description.abstract | Although electroconvulsive therapy (ECT) has been used to treat schizophrenia since its inception in 1938, its efficacy as long-term treatment is still controversial. A 2-Phase, prospective study has been conducted in 21 patients with schizophrenia. The duration of study was 1 year. Bilateral ECT combined with flupenthixol (18-24 mg/day) was used throughout. Brief Psychiatric Rating Scale (BPRS), Global Assessment of Functioning (GAF), and Mini-Mental-State Exam (MMSE) were used to measure the outcome. No patients suffered relapses. There were marked reductions in BPRS scores (73 per cent and 70 per cent), and increases in GAF scores (68 per cent and 91 per cent), at the end of Phases I and II, respectively. This study suggests a long-term efficacy of ECT combined with neuroleptic therapy in patients with schizophrenia. | - |
dc.subject | flupentixol | - |
dc.subject | neuroleptic agent | - |
dc.subject | adolescent | - |
dc.subject | adult | - |
dc.subject | article | - |
dc.subject | Brief Psychiatric Rating Scale | - |
dc.subject | clinical trial | - |
dc.subject | drug resistance | - |
dc.subject | electroconvulsive therapy | - |
dc.subject | female | - |
dc.subject | human | - |
dc.subject | long term care | - |
dc.subject | male | - |
dc.subject | methodology | - |
dc.subject | multimodality cancer therapy | - |
dc.subject | phase 1 clinical trial | - |
dc.subject | phase 2 clinical trial | - |
dc.subject | prognosis | - |
dc.subject | prospective study | - |
dc.subject | schizophrenia | - |
dc.subject | treatment failure | - |
dc.subject | treatment outcome | - |
dc.subject | Adolescent | - |
dc.subject | Adult | - |
dc.subject | Antipsychotic Agents | - |
dc.subject | Brief Psychiatric Rating Scale | - |
dc.subject | Combined Modality Therapy | - |
dc.subject | Drug Resistance | - |
dc.subject | Electroconvulsive Therapy | - |
dc.subject | Female | - |
dc.subject | Flupenthixol | - |
dc.subject | Humans | - |
dc.subject | Long-Term Care | - |
dc.subject | Male | - |
dc.subject | Prognosis | - |
dc.subject | Prospective Studies | - |
dc.subject | Schizophrenia | - |
dc.subject | Treatment Failure | - |
dc.subject | Treatment Outcome | - |
dc.title | Maintenance ECT in Treatment-Resistant Schizophrenia | - |
dc.type | Article | - |
dc.rights.holder | Scopus | - |
dc.identifier.bibliograpycitation | Journal of the Medical Association of Thailand. Vol 83, No.6 (2000), p.657-662 | - |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.